Compare Five Below Inc (FIVE) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Moderna, Inc. — how do they compare? Five Below Inc trades at $211.87 (market cap $11.55B), while Moderna, Inc. trades at $203.11 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 6.8× Five Below Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Moderna, Inc. for 59 Days on average.
| FIVE | MRNA | |
|---|---|---|
Market Cap | $11.55B | $78.65B |
Volume | 1,120,554 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $203.46 |
52-Week Low | $138.49 | $22.36 |
Typical Hold Time | 46 Days | 59 Days |
Enterprise Value | $12.40B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $204.24, down 2.71% today, with strong analyst support (60% buy ratings) and a consensus price target of $298.44. The stock shows robust fundamentals with revenue growth from $3.6B in 2024 to $3.9B in 2025 and projected $5.3B in 2026, alongside consistent earnings beats. Technical indicators are mixed with a bearish overall signal but bullish oscillators, while recent news highlights digital marketing initiatives and board appointments.
FIVE presents a compelling growth story with raised 2026 guidance and strong profitability metrics (ROE 28.25%), though premium valuation (P/E 18.81) and execution risks amid consumer spending pressures warrant caution. Upside potential exists if traffic and margin trends sustain, but investors should monitor inflation impacts on discretionary retail spending.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
